COHANCE · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 26/100 — Quality 58 · Valuation 11 · Growth 14 · Momentum 0
| Share price | ₹450.70 |
| Market cap | ₹11,858 Cr |
| P/E ratio | 61.4 |
| P/B ratio | 3.1 |
| ROE | 19.0% |
| ROCE | 13.3% |
| Book value | ₹99.19 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,269 Cr | ₹150 Cr | 19.0% |
| 2025 | ₹1,198 Cr | ₹265 Cr | 31.0% |
| 2024 | ₹1,051 Cr | ₹300 Cr | 39.0% |
| 2023 | ₹1,340 Cr | ₹411 Cr | 43.0% |
| 2022 | ₹1,320 Cr | ₹454 Cr | 44.0% |
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and